Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

2.680 +0.110 (+4.28%)

Official Closing Price Updated: 4:00 PM EDT, Aug 1, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	16,672,592
Open	2.500
Bid (Size)	2.740 (20)
Ask (Size)	2.760 (9)
Prev. Close	2.570
Today's Range	2.450 - 2.710
52wk Range	1.639 - 12.51
Shares Outstanding	305,252,194
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Is Iovance Biotherapeutics Stock Due for a Big Rally?

July 30, 2025

The biotech stock has been picking up steam of late -- but will it last?

Via The Motley Fool

This Beaten-Down Healthcare Stock Could Jump 720%, According to a Wall Street Analyst. Is It Time to Buy?

July 29, 2025

Even the average price estimate for this stock suggests it can soar, but not everyone's convinced.

Via The Motley Fool

Performance

YTD	-65.6%	-65.6%
1 Month	+53.1%	+53.1%
3 Month	-23.4%	-23.4%
6 Month	-52.5%	-52.5%
1 Year	-65.6%	-65.6%

More News

Iovance Biotherapeutics to Host Second Quarter and First Half 2025 Financial Results and Corporate Updates Webcast on Thursday, August 7, 2025

July 24, 2025

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's Intraday Session

July 24, 2025

Via Benzinga

Here are the top movers in Wednesday's session.

July 23, 2025

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Intraday Session

July 23, 2025

Via Benzinga

GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday

July 23, 2025

Via Benzinga

These stocks are gapping in today's session

July 23, 2025

Via Chartmill

Analyst Expectations For Iovance Biotherapeutics's Future

July 23, 2025

Via Benzinga

Health In Tech (NASDAQ: HIT) Posts Blowout Q2, Stock Responds – HIT, SNYR, PNPN.V/PNPNF in Breakout Zone; See More to Watch Inside

July 22, 2025

Via AB Newswire

Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock

July 22, 2025

Via Investor's Business Daily

D.R. Horton, IQVIA Holdings, Northrop Grumman And Other Big Stocks Moving Higher On Tuesday

July 22, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

July 22, 2025

Via Benzinga

This Healthcare Stock Just Hit a 52-Week Low -- but Wall Street Sees 380% Upside

July 21, 2025

Via The Motley Fool

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

July 18, 2025

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

IOVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

July 15, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

July 15, 2025

Via Benzinga

Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer

July 15, 2025

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

July 14, 2025

From Faruqi & Faruqi, LLP

Via Business Wire

FINAL IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Investors in Iovance Biotheapeutics, Inc. (IOVA) to Inquire About Their Rights in Class Action Lawsuit

July 14, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA

July 14, 2025

From Pomerantz LLP

Via GlobeNewswire

Class Action Filed Against Iovance Biotherapeutics, Inc. (IOVA) - July 14, 2025 Deadline to Join - Contact Levi & Korsinsky

July 14, 2025

Via NewMediaWire

Class Action Filed Against Iovance Biotherapeutics, Inc. (IOVA) - July 14, 2025 Deadline to Join - Contact Levi & Korsinsky

July 14, 2025

Via TheNewswire.com

Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma

July 14, 2025

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Iovance Biotherapeutics, Inc. and Urgently Encourages Investors to Contact the Firm

July 12, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Frequently Asked Questions

Is Iovance Biotherapeutics, Inc. - Common Stock publicly traded?

Yes, Iovance Biotherapeutics, Inc. - Common Stock is publicly traded.

What exchange does Iovance Biotherapeutics, Inc. - Common Stock trade on?

Iovance Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock?

The ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock is IOVA on the Nasdaq Stock Market

What is the current price of Iovance Biotherapeutics, Inc. - Common Stock?

The current price of Iovance Biotherapeutics, Inc. - Common Stock is 2.680

When was Iovance Biotherapeutics, Inc. - Common Stock last traded?

The last trade of Iovance Biotherapeutics, Inc. - Common Stock was at 08/01/25 04:00 PM ET

What is the market capitalization of Iovance Biotherapeutics, Inc. - Common Stock?

The market capitalization of Iovance Biotherapeutics, Inc. - Common Stock is 818.08M

How many shares of Iovance Biotherapeutics, Inc. - Common Stock are outstanding?

Iovance Biotherapeutics, Inc. - Common Stock has 818M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.